In France, French citizens with an annual income less than 10339 euros are considered living with low-income and are eligible to benefit from a public universal healthcare insurance coverage called C2S (complémentaire santé solidaire). C2S covers primary care and hospital care. Non-citizens with low income, like some migrants, can also benefit from a public healthcare insurance coverage called AME ("Aide Medicale d'Etat" for State Medical Aid). These criteria are used as a marker of precarity settings (i.e., socio-economic vulnerability) in France. In France, HIV-related care and treatments are reimbursed at 100% (ALD30), whatever the level of precariousness. ART adherence has been shown significantly lower in PLWH with C2S health insurance coverage. Although BIC/FTC/TAF is a recommended preferred option in naive PLWH and in switch or maintenance therapy in most settings, due to the forgiveness profile and the high genetic barrier to resistance, boosted darunavir (DRV/r) remains even more widely used than 2nd generation InSTIs in populations in precarity settings, and Real World Effectiveness (RWE) with BIC/FTC/TAF is missing to better support its use in these settings.
Paris Bichat Hospital (located in one of the poorest districts in the Ile-de-France region) and Nantes university hospital (West France region) follow a cohort of PLWH with a high proportion of populations in precarity settings (i.e with C2S and AME health insurance coverage): Paris Bichat hospital: N=5143 PLWH (December 2021), sex ratio F/M 37/56%, Transgender Women 7%, and born in sub-Saharan African countries 49%. Nantes university hospital: N=2227 PLWH (December 2021), sex ratio F/M 35/65% and born in sub-Saharan African countries 33%. In this cohort of 7370 PLWH in both sites 50% are receiving an InSTI-based ART regimen, regardless of prior treatment history, and at least 40% are receiving care through the C2S or AME, respectively.

Start Date01 Sep 2025

Sponsor / Collaborator-

NCT07055451

/ RecruitingPhase 1

A Phase 1b Study to Evaluate the Safety and Pharmacokinetics of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) in Neonates Exposed to HIV-1

The goal of this clinical study is to learn more about the study drug, Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF), safety, tolerability, and pharmacokinetics (how B/F/TAF is absorbed, modified, distributed, and removed from the body of the participants) in neonates exposed to human immunodeficiency virus type 1 (HIV-1).
The primary objective of this study is to evaluate the safety and plasma pharmacokinetics (PK) (how B/F/TAF is absorbed, modified, distributed, and removed from the body of the participants) of B/F/TAF tablet for oral suspension (TOS) in full-term neonates exposed to HIV-1 but uninfected.

Start Date12 Aug 2025

Sponsor / Collaborator

Gilead Sciences, Inc.

ChiCTR2500108287

/ RecruitingNot ApplicableIIT

A Multi-center Randomized Clinical Trial on BIC/FTC/TAF vs DTG+3TC+TDF in People with HIV Who Experience Virologic Failure in China

Start Date01 May 2025

Sponsor / Collaborator-

100 Clinical Results associated with Bictegravir/Emtricitabine/Tenofovir Alafenamide Fumarate

100 Translational Medicine associated with Bictegravir/Emtricitabine/Tenofovir Alafenamide Fumarate

100 Patents (Medical) associated with Bictegravir/Emtricitabine/Tenofovir Alafenamide Fumarate

139

Literatures (Medical) associated with Bictegravir/Emtricitabine/Tenofovir Alafenamide Fumarate

31 Dec 2025·JOURNAL OF MEDICAL ECONOMICS

Treatment persistence among treatment-experienced people with HIV switching to integrase strand transfer inhibitor–based antiretroviral regimens

Article

Author: Chen, Megan ; de Boer, Melanie ; Trom, Cassidy ; Chuo, Ching-Yi ; Christoph, Mary J. ; Zachry, Woodie

AIMS:

Low rates of persistence are associated with poor outcomes in people with HIV (PWH). This retrospective cohort study assessed treatment persistence as measured by time to treatment switch in treatment-experienced (TE) PWH initiating integrase strand transfer inhibitor (INSTI)-based regimens.

METHODS:

United States prescription claims and medical history data from the IQVIA Longitudinal Access and Adjudication Dataset between January 1, 2018, and August 31, 2023, were analyzed. TE PWH with ≥1 prescription claim for initiation of an INSTI-based antiretroviral regimen during the index period (January 1, 2020, to December 31, 2022) were included. Descriptive analyses of demographic and comorbidity variables were performed, stratified by regimen. Kaplan-Meier analysis was used to evaluate time to subsequent treatment switch in the overall population and among PWH aged ≥50 years, those receiving Medicare, and those with mental health conditions or substance use disorders.

RESULTS:

Overall, 29,348 TE PWH were included. The majority of INSTI-based regimen initiations were for bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) (61%; n = 17,917), followed by dolutegravir/lamivudine (27.4%; n = 8034) and cabotegravir + rilpivirine (7.4%; n = 2186). A subsequent switch occurred in 3341 (11.4%) PWH. Risk factors for switch included female sex, Medicare/Medicaid coverage, and higher Charlson Comorbidity Index scores. B/F/TAF was associated with the fewest subsequent switches (9.2%; n = 1656) and was significantly less likely than any other regimen to lead to a subsequent switch, either in the overall population or in the three at-risk subgroups.

LIMITATIONS:

No data are available to determine the underlying reasons for initial treatment choice or subsequent treatment switch.

CONCLUSIONS:

This study provides evidence for greater treatment persistence with B/F/TAF versus other INSTI-based regimens. Unlike prior studies that focused on treatment-naïve individuals, this analysis uniquely evaluates persistence among treatment-experienced PWH initiating newer INSTI-based regimens.

31 Dec 2025·HIV Research & Clinical Practice

Bictegravir/emtricitabine/tenofovir alafenamide in clinical practice for people with HIV: final 24-month effectiveness and safety outcomes in key populations in the observational BICSTaR cohort

Article

Author: Uriel, Alison ; Watanabe, Dai ; Robineau, Olivier ; Choy, Chiaw Yee ; Mallolas, Josep ; Marchetti, Giulia ; Thorpe, David ; Yang, Chia-Jui ; Vogelmann, Roger ; Berrevoets, Marvin ; D’Amato, Lisa ; Heinzkill, Marion ; Ramroth, Johanna ; Trottier, Benoit ; De Barra, Eoghan ; Marongiu, Andrea ; Elbirt, Daniel ; Lee, Sun Hee ; Gündüz, Alper

BACKGROUND:

BICtegravir Single Tablet Regimen (BICSTaR) is an observational cohort study evaluating the effectiveness and safety of bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in treatment-naïve (TN) and treatment-experienced (TE) people with HIV.

OBJECTIVE:

To present final pooled 24-month outcomes for the full cohort.

METHODS:

Prospective data were pooled from TN and TE adults with HIV initiating B/F/TAF in routine clinical practice across 14 countries (data collection: 25/06/2018-29/12/2023). Outcomes at 24 months included virologic suppression (HIV-1 RNA <50 copies/mL), immunologic effectiveness (change in CD4 cell count and CD4/CD8 ratio), persistence, and safety. Outcomes were also analysed in key populations.

RESULTS:

Of 2,074 (483 TN, 1,591 TE) participants included, most were male (85%), White (70%), and had ≥1 comorbidity (66%). Median (Q1, Q3) age was 45 (35, 54) years. At 24 months, 94% of TN and 96% of TE participants had HIV-1 RNA <50 copies/mL (missing = excluded analysis). These values were 88% and 86%, respectively, in a discontinuation = failure analysis. Effectiveness remained high across all key populations at 24 months. Median (Q1, Q3) CD4 count increased by 257 (127, 447) cells/µL in TN and 40 (-70, 153) cells/µL in TE participants (both p < 0.001). There was no reported treatment-emergent resistance to B/F/TAF. Persistence was high at 24 months (TN, 95%; TE, 91%). Drug-related adverse events occurred in 11% of TN and 12% of TE participants, leading to B/F/TAF discontinuation in 5%.

CONCLUSIONS:

B/F/TAF was generally well tolerated over 24 months, with high effectiveness and persistence observed among a broad range of people with HIV.

01 Nov 2025·HIV MEDICINE

Suppressed switch to Bictegravir/emtricitabine/tenofovir alafenamide compared with dolutegravir/lamivudine: Real‐world evidence from the OPERA cohort

Article

Author: Sension, Michael G. ; Brunet, Laurence ; Gruber, Joshua ; Fusco, Gregory P. ; Dunbar, Megan S. ; Dieterich, Douglas T. ; Pierone, Gerald ; Fusco, Jennifer S.

Abstract:

Objectives:

To compare the virologic effectiveness and discontinuation of the commonly prescribed fixed‐dose combination 3‐drug and 2‐drug regimens, bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) and dolutegravir/lamivudine (DTG/3TC), in virologically suppressed individuals in routine clinical care in the US.

Methods:

From the OPERA cohort, ART‐experienced, virologically suppressed (viral load <200 copies/mL) adults with HIV who switched to B/F/TAF or DTG/3TC (01AUG2020‐30JUN2022) were followed through 31DEC2022, death, loss to follow‐up or discontinuation. Cox proportional hazard models with stabilized inverse probability of treatment weights were used to assess the association between regimen and time to confirmed virologic failure (cVF 200 ; 2 viral loads ≥200 copies/mL or 1 viral load ≥200 copies/mL + discontinuation) or time to discontinuation.

Results:

A total of 3512 B/F/TAF users were followed for a median of 16 months (IQR: 11, 22); 2327 DTG/3TC users were followed for a median of 15 months (IQR: 10, 21). cVF 200 was observed among 2% of B/F/TAF and 3% of DTG/FTC users, for an adjusted hazard ratio of 0.84 (95% CI: 0.59, 1.18) for B/F/TAF compared with DTG/3TC. Regimen discontinuation was observed among 17% of B/F/TAF and 19% of DTG/3TC users, for an adjusted hazard ratio of 0.83 (95% CI: 0.73, 0.94) for B/F/TAF compared with DTG/3TC. Treatment‐related reasons for discontinuation represented 6% of B/F/TAF and 9% of DTG/3TC discontinuations.

Conclusions:

In this large US cohort, both B/F/TAF and DTG/3TC were well tolerated and effective treatment options among virologically suppressed individuals in routine clinical care, although DTG/3TC tended to be discontinued faster than B/F/TAF.

188

News (Medical) associated with Bictegravir/Emtricitabine/Tenofovir Alafenamide Fumarate

28 Nov 2025

·www.pharmaceutical-technology.com

Over half of European HIV patients diagnosed late, ECDC report finds

The ECDC’s 2025 HIV Surveillance Report has found that 54% of patients diagnosed with HIV in 2024 were diagnosed too late to receive fully effective treatment. Image credit: Corona Borealis Studio via Shutterstock.com. A European 2025 HIV/AIDS surveillance report has revealed that countries within the continent are currently failing to test and treat HIV early. The annual report, published by the European Centre for Disease Prevention and Control (ECDC), was released on 27 November 2025 but looks at 2024 data. While the report identified a small downturn in HIV cases between 2023 and 2024, testing gaps were still highly prevalent. This is evidenced by the fact that 54% of patients with HIV across the World Health Organization (WHO) European region in 2024 were unable to receive optimal treatment due to late diagnosis. This is notable as patients with a delayed HIV diagnosis are less likely to gain the full benefits of antiretroviral (ART) therapies. Currently, ART therapies are the mainstay treatment option for patients diagnosed with HIV, as they can suppress viral load and prevent transmission. According to the annual report, 105,922 HIV diagnoses were made across the WHO European region in 2024, which includes 53 countries. Of those receiving late diagnoses, the highest proportion were heterosexual patients – especially men – as well as people that inject drugs. As current testing initiatives across Europe are currently failing to diagnose a majority of patients early, the ECDC noted that the 2030 goal of ending AIDS as a public health threat could be in jeopardy. GlobalData Strategic Intelligence US Tariffs are shifting - will you react or anticipate? Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis. By GlobalData Learn more about Strategic Intelligence To ensure this goal is achieved, the ECDC and the WHO’s European division are calling for the scale-up and routinisation of HIV testing across the continent, with a key focus on self-testing and community-based options. According to Hans Henri P. Kluge, WHO regional director for Europe, tackling the silent HIV crisis will involve “removing the deadly barriers of stigma and discrimination” that currently discourage individuals from seeking out a HIV test. Meanwhile, Pamela Rendi-Wagner, director of the ECDC, stressed the importance of innovating testing strategies, while “ensuring rapid linkage to care” to improve patient outcomes. A major hit to global HIV treatment efforts came this year came when President Donald Trump cut a large amount of funding for foreign aid. This impacted HIV, malaria and tuberculosis treatment services in low-income countries supported by the United States Agency for International Development (USAID). Trump also trimmed financial support for the president’s Emergency Plan for AIDS Relief (PEPFAR). The plan has become a major pillar in fighting the global HIV/AIDS response, providing testing services, antiretroviral treatment and education programmes. HIV treatments advance Currently, HIV remains a major threat to public health, with the WHO estimating that 40.8 million were living with the disease globally at the end of 2024. However, there are a wide range of effective ART options available to patients, meaning that those with access to medications have a similar life expectancy to an individual living without HIV. The most widely prescribed ART is currently Gilead’s Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide), which had a strong financial showing in Q2 2025, with sales jumping 9% to $3.5bn. While the drug’s patent is up for expiry as early as October 2027, GlobalData analysts predict that no other HIV therapy is likely to surpass Biktarvy in terms of commercial success. Alongside Biktarvy, Gilead has found a new key asset in Yeztugo (lenacapavir), which the US Food and Drug Administration (FDA) approved as a biannual pre-exposure prophylaxis (PrEP) for patients at risk of HIV in June 2025. While this treatment is only suitable as a preventive measure, GlobalData analysts note that the therapy is set to revolutionise the HIV landscape. Now, some companies are looking to cure HIV completely. This includes American Gene Technologies, which is currently looking to take its potentially curative cell therapy, AGT103-T, to additional trials after a Phase I study yielded promising results . The International AIDS Vaccine Initiative is also working towards a preventive vaccine for HIV, which has seen an adenovirus vaccine enter Phase I clinical trials in Africa. Currently, the jab is being tested in both HIV-positive and HIV-negative individuals. Pharmaceutical Technology Excellence Awards - The Benefits of Entering Gain the recognition you deserve! The Pharmaceutical Technology Excellence Awards celebrate innovation, leadership, and impact. By entering, you showcase your achievements, elevate your industry profile, and position yourself among top leaders driving pharmaceutical advancements. Don’t miss your chance to stand out—submit your entry today! Nominate Now

VaccinePhase 1Clinical ResultDrug Approval

20 Nov 2025

·pharma.economictimes.indiatimes.com

Merck's oral HIV treatment non-inferior to Gilead's Biktarvy in late-stage trial

Bengaluru: Merck said on Wednesday its experimental oral HIV medicine was found to be non-inferior to Gilead Sciences' top-selling drug Biktarvy in a late-stage study involving previously untreated adult patients. The data showed that an oral combination regimen of doravirine and islatravir showed suppression of the HIV-1 virus at similar levels as Biktarvy at week 48, Merck said. Its safety profile was also comparable to Gilead's drug, which has become the standard of care for HIV-1 treatment . Biktarvy and Merck's drug are antiretroviral treatments , combinations of medicines used to stop reproduction of the virus. HIV-1 is the most common strain of the retrovirus that causes Acquired Immunodeficiency Syndrome, commonly known as AIDS. "Despite these positive findings, we do not anticipate today's readout to create a near-term shift in the HIV treatment paradigm," BMO Capital Markets analyst Evan Seigerman said, adding that there needs to be more "granular data" to be confident about the safety of Merck's drug. The company plans to present detailed findings from the trial at a future medical meeting and submit applications including these data to health authorities. The U.S. Food and Drug Administration is set to make its decision on approval for Merck's oral drug by April 28. While islatravir is an experimental treatment, Merck's doravirine is already approved and sold in the U.S. under the brand Pifeltro for HIV-1 treatment in combination with other antiretrovirals, and as a single-tablet regimen, Delstrigo. Islatravir is currently being tested in multiple trials in combination with other antiretrovirals for potential daily and once-weekly treatments for HIV-1. Last year, the doravirine and islatravir combination was shown to be non-inferior to Biktarvy in suppressing the replication of HIV-1 in patients who were already on antiretroviral therapy. (Reporting by Sneha S K in Bengaluru; Editing by Tasim Zahid and Leroy Leo)

Clinical StudyClinical ResultDrug Approval

19 Nov 2025

·endpoints.news

Merck says once-daily HIV drug combo succeeds in another Phase 3

Merck secured another win on Wednesday in its plan to bolster its HIV portfolio. The pharma giant said its two-drug combination was non-inferior to a three-drug package in a Phase 3 trial in adults with HIV-1 who were not previously on antiretroviral treatment. Merck said the study of the single-tablet combination of doravirine and islatravir met the primary efficacy hypothesis at week 48. The safety of DOR/ISL was also “comparable” to the three-drug combination of Gilead’s Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide, or BIC/FTC/TAF). Both are once-daily regimens. DOR/ISL is already under FDA review for a different patient population : people with HIV who are already on an antiretroviral regimen. The regulatory body is slated to decide whether to approve the treatment in that population by April 28 . Merck hopes DOR/ISL will become part of a broader HIV portfolio that could be a $5 billion business . Its existing medicines in the space made $412 million in revenue in the first half of this year, but it’s studying additional combinations and a once-monthly oral PrEP that just entered Phase 3. Merck has been involved in HIV science since the early days of the epidemic, and brought the protease inhibitor Crixivan to market in 1996. Multiple HIV treatment options now exist, and companies like Gilead and GSK’s ViiV make long-acting HIV medicines, but for different patient populations. Merck’s existing HIV work is a small piece of the pharma’s efforts to pad the revenue gap that will come from Keytruda’s patent cliff. Merck has spent more than $19 billion this year on acquisitions, namely for respiratory biotech Verona Pharma and influenza antiviral developer Cidara Therapeutics . The new Phase 3 data will be presented at a future medical conference. Merck said it plans to use the data in applications to health regulators. With the non-inferiority results, Merck hopes to go up against Biktarvy, which brought in $3.7 billion in sales for Gilead in the third quarter of this year. “These data support the potential for this regimen to be a meaningful treatment option for virally suppressed people living with HIV who are looking to switch to a new regimen or people who have not previously been on antiretroviral therapy to start treatment,” Merck Research Laboratories chief medical officer Eliav Barr said in a press release. Merck chief marketing officer Chirfi Guindo said on an investor call in July that the company believes DOR/ISL will be “the preferred switch option for many individuals.” Guindo said the drug combination provides “robust viral control” and a “high barrier to resistance.” Doravirine is an approved HIV medicine known as Pifeltro and part of an HIV pill marketed as Delstrigo. Islatravir, meanwhile, is in multiple clinical trials assessing whether it can be a once-daily or weekly treatment for HIV when paired up with other medicines. The drug is in Phase 3 with Gilead’s lenacapavir as a potential once-weekly oral treatment. Islatravir is also in a Phase 2b in combination with Merck’s ulonivirine, an experimental non-nucleoside reverse transcriptase inhibitor (NNRTI). That pairing is “back on track,” Luisa Stamm, Merck’s associate VP and section head for HIV, said in an interview with Endpoints in July. The drug combo had a safety signal for a prior Phase 2, but Merck is now looking at a lower dosing schedule to assuage concerns.

Phase 3Phase 2AcquisitionClinical Result

100 Deals associated with Bictegravir/Emtricitabine/Tenofovir Alafenamide Fumarate

External Link

KEGG	Wiki	ATC	Drug Bank
-	-	J05AR	-

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
HIV Infections	United States	Gilead Sciences, Inc.	07 Feb 2018

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Fasting	Phase 3	United States	Merck Sharp & Dohme Corp.	01 Aug 2022
Metabolic Syndrome	Phase 3	United States	Merck Sharp & Dohme Corp.	01 Aug 2022
Obesity	Phase 3	United States	Merck Sharp & Dohme Corp.	01 Aug 2022
Hepatitis B	Phase 3	United States	Gilead Sciences, Inc.	30 May 2018
Hepatitis B	Phase 3	China	Gilead Sciences, Inc.	30 May 2018
Hepatitis B	Phase 3	Japan	Gilead Sciences, Inc.	30 May 2018
Hepatitis B	Phase 3	Dominican Republic	Gilead Sciences, Inc.	30 May 2018
Hepatitis B	Phase 3	France	Gilead Sciences, Inc.	30 May 2018
Hepatitis B	Phase 3	Greece	Gilead Sciences, Inc.	30 May 2018
Hepatitis B	Phase 3	Hong Kong	Gilead Sciences, Inc.	30 May 2018

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT05122754 (Pubmed \| Infect Dis Ther)	Phase 3	HIV Infections	150	Bictegravir/Emtricitabine/Tenofovir Alafenamide	stizrqkutn(hhvqunovux) = ssirsuujcn dflsapxngb (quzrnfvklk, 0.20 - 4.12) View more	Positive	21 Nov 2025
				Tenofovir Disoproxil Fumarate-Based Regimens	stizrqkutn(hhvqunovux) = precjgkrqj dflsapxngb (quzrnfvklk, −0.52 - 3.15) View more
NCT04734652 (INSIGHT, CTgov)	Phase 2	Acquired Immunodeficiency Syndrome \| Pulmonary Tuberculosis	122	Biktarvy® (BIC Arm)	crlmyxmztd = yiuqgpzjqu lnwggynhji (xlcymtslsm, nbbmxvgtnx - cmmzmugduz) View more	-	15 Aug 2025
				Tenofovir+Dolutegravir+Lamivudine (DTG Arm)	crlmyxmztd = apooesplvv lnwggynhji (xlcymtslsm, hlteggapqh - plqbttljtm) View more
NCT03580668 (BICSTaR, BusinessWire) Manual	Not Applicable	HIV Infections	-	Biktarvy (treatment‐naïve)	fhqmuddfbq(wwwpelxvnv) = nsbykrgpxw frhfmqfqwl (fimpoftoba ) View more	Positive	12 Nov 2024
				Biktarvy (treatment‐experienced)	fhqmuddfbq(wwwpelxvnv) = ljqjediymy frhfmqfqwl (fimpoftoba ) View more
NCT03547908 (ALLIANCE, BusinessWire) Manual	Phase 3	Hepatitis B \| HIV Infections	-	Biktarvy	qnbvcdsajt(gkjmzrbvaq) = hcpqgswcqk sdfjfifwod (rtaowqzdei ) View more	Positive	12 Nov 2024
NCT02607956 \| NCT02607930 (Study 1489; Study 1490, Pubmed \| Future Microbiol)	Phase 3	HIV Infections	-	Bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF)	bfneeisjao(ojcpfwlmka) = hdovortorv jnvfxlhmwo (gdvtaxnrzo ) View more	Positive	04 Sep 2024
NCT04416906 (Pubmed \| J Antimicrob Chemother) Manual	Phase 3	HIV Infections First line	100	Bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF)	lmbtlpjijj(upmvatwdmu) = ylruiuolci eqlapvgsow (unvqhlabnq ) View more	Positive	24 Jul 2024
NCT02607956 \| NCT02607930 (Studies 1489 and 1490, Pubmed \| AIDS)	Phase 3	HIV Infections	519	Bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF)	gifcewljys(mbdkbgmeph) = Two participants discontinued B/F/TAF due to treatment-related AEs ugyaercdqq (nqlmlcodez ) View more	Positive	01 Jun 2024
				Dolutegravir/F/TAF
NCT06177574 (BIC-NOW, Pubmed \| Int J Antimicrob Agents) Manual	Phase 4	HIV Infections First line	208	Bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF)	xujprnkzxj(tescvkorhw) = uctukjejfd ylrwsljsws (etyyxugwph, 80 - 99) View more	Positive	02 Apr 2024
NCT03547908 (ALLIANCE, Corporate Publications) Manual	Phase 3	Hepatitis B \| Coinfection \| HIV Infections	243	Biktarvy	djzeajagah(xpzhtmpznz) = upper respiratory tract infection (19.8% vs. 14.8%), COVID-19 (38% vs. 36.1%), pyrexia (12.4% vs. 13.1%), ALT increase (8.3% vs. 12.3%), and nasopharyngitis (12.4% vs. 6.6%). wexwwapxrq (peohkmffat )	Positive	06 Mar 2024
				dolutegravir+emtricitabine+tenofovir disoproxil fumarate
NCT04734652 (INSIGHT, BusinessWire) Manual	Phase 2	Tuberculosis \| Coinfection \| HIV Infections	-	Biktarvy	ysmcghaotv(ypbsrmzicq) = eeqmjwnexk kngmjrahca (ubthfmofje )	Positive	06 Mar 2024
				dolutegravir+lamivudine+tenofovir disoproxil fumarate	ysmcghaotv(ypbsrmzicq) = chftmwjbdv kngmjrahca (ubthfmofje )

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Bictegravir/Emtricitabine/Tenofovir Alafenamide Fumarate

Overview

Basic Info

Structure/Sequence

Related

External Link

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation